ArticlePloS one2025
Willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among black cisgender women in the Southern United States.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Developing and assessing acceptability of a shared decision-making tool for selecting among HIV pre-exposure prophylaxis options in the United States of America.PLOS global public health · 2026Article
- A Theory Informed Multi-Component Intervention to Promote Family Medicine Provider PrEP Prescription to Adolescent Girls and Young Women in the U.S. Southeast: Pilot Trial Results.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLong-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention may improve adherence for those with concerns with daily pills. Limited data exist on LAI-PrEP acceptability among Black women in the U.S., a population vulnerable to HIV. We assessed willingness to use LAI-PrEP among Black women eligible for PrEP in the Southern U.S.
methodsWe conducted a cross-sectional online survey of HIV-negative Black women from March to June 2022 in the U.S. South. Participants provided information on sociodemographic characteristics, HIV knowledge, PrEP awareness, and use, stigma, risk perception, medical mistrust, and healthcare access. Multivariate logistic regression models determined factors associated with willingness to use LAI-PrEP.
resultsOf 491 women, the mean (SD) age was 40.1 (17.5), 53% of participants had a college degree or lower, 79% were single, and 80% resided in urban/suburban settings. Thirty-nine percent were aware of PrEP before the study and 36.7% of women were willing to use LAI-PrEP. In multivariate analyses, PrEP awareness [adjusted odds ratio (aOR=2.37, 95% CI 1.40, 3.73, p < 0.001), having a personal clinician (aOR=2.01, 95% CI 1.10, 3.68, p = 0.02), HIV worried (aOR=1.78, 95% CI 1.09, 2.89, p = 0.02), and medical trust (aOR=1.41, 95% CI 1.03, 1.93, p = 0.04) were statistically associated with willingness to use LAI-PrEP. However, the healthcare stereotype (beliefs that healthcare is biased) had lower odds of using LAI-PrEP (aOR=0.94, 95% CI 0.89, 0.99, p = 0.04).
conclusionBlack women at risk for HIV are more likely to consider injectable PrEP when they understand HIV risk factors, are aware of PrEP, have a clinician, and trust the medical care. Implementing client-centered care interventions could effectively address medical mistrust and enhance engagement in HIV prevention services among Black women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.